Summary
Vertex Pharmaceuticals Inc. reported its financial results for the quarter and six months ended June 30, 2008. The company experienced a significant increase in total revenues, primarily driven by a substantial rise in collaborative and other research and development revenues, largely attributed to milestone payments from its Janssen collaboration for the development of telaprevir. Despite this revenue growth, Vertex continued to incur net losses, though the loss for the second quarter decreased by 22% compared to the prior year, and the six-month loss decreased by 6%. The company's cash position strengthened considerably, ending the period with $832.1 million in cash, cash equivalents, and marketable securities, bolstered by recent debt and equity offerings and the sale of a royalty stream. Management highlighted the ongoing substantial investments in research and development, particularly for telaprevir in Phase 3 trials for Hepatitis C and VX-770 for Cystic Fibrosis, which are expected to increase in the latter half of the year. The company anticipates needing significant additional capital to fund the completion of telaprevir's development and commercialization, as well as other pipeline programs, despite projecting sufficient liquidity for the next twelve months based on current cash and expected collaborator payments.
Key Highlights
- 1Total revenues increased by 82% to $69.4 million for the three months ended June 30, 2008, driven by a 119% increase in collaborative R&D revenues.
- 2Net loss for the three months ended June 30, 2008, decreased by 22% to $91.3 million, or ($0.66) per share, compared to the same period in 2007.
- 3Cash, cash equivalents, and marketable securities increased significantly to $832.1 million as of June 30, 2008, up from $467.8 million at the end of 2007, due to recent financing activities.
- 4The company completed a concurrent offering of $287.5 million in convertible senior subordinated notes and sold 6.9 million shares of common stock in February 2008.
- 5In May 2008, Vertex sold its right to future royalty payments from Lexiva/Telzir and Agenerase for $160.0 million, recognizing $155.1 million as deferred revenue to be recognized over the license agreement term.
- 6Research and Development expenses decreased by 7% to $127.1 million for the three months ended June 30, 2008, primarily due to a reduction in commercial supply investment in telaprevir and contractual services.
- 7Vertex expects significant future capital requirements to fund the development and potential commercialization of telaprevir and other pipeline candidates.